Trial reportThe oncologist2026
Home-based supervised exercise on metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 2 study.
Trial report in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundQUALIOR-phase 2 multicenter trial explored the feasibility of a home-based supervised physical exercise program (SPEP) in metastatic cancer patients receiving oral targeted therapies.
methodsPatients with metastatic cancers receiving oral targeted therapies were randomized (2:1) to a 3-month home-based SPEP (with a coach at home) or recommended adapted physical exercises (booklet). Primary endpoint was feasibility defined as the rate of patients who performed at least 50% of the theoretically planned sessions in the SPEP arm. Main secondary endpoints were fatigue and pain evaluated by visual analogue scales (VAS) during the program.
resultsAmong 112 patients, 74 and 38 were included in the SPEP and control arms, respectively. Median age was 59 (range: 31-83) years and the majority of patients were women. Main primary tumor location was breast (57%) and kidney (16%). Thirty-three (30%) patients were treated with anti-angiogenic tyrosine kinase inhibitors, and 53 (47%) received epidermal growth factor receptor or cell cycle inhibitors. Forty-five (61%) patients performed at least 50% of the SPEP. Median fatigue decreased from 4 to 3 (range: 0-10) after 3 months in the SPEP group with maintain of pain control. The percentage of patients with high level VAS of fatigue at 3 months was lower in SPEP arm than in the control arm (27% vs. 62%, P = .004).
conclusionsQUALIOR showed that SPEP with a coach at home was feasible in patients with metastatic cancers treated with oral targeted therapies. This program could mitigate the fatigue induced by oral targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.